Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 5.22 2.55% 0.13
SYRS closed up 2.55 percent on Friday, May 14, 2021, on 1.53 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical SYRS trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 2.55%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.55%
Outside Day Range Expansion 2.55%
Older End-of-Day Signals for SYRS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 2 days ago
Possible NR7 2 days ago
10 DMA Resistance 2 days ago
Rose Above 10 DMA 2 days ago
3x Volume Pace 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Syros Pharmaceuticals, Inc. Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Diseases Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia

Is SYRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.65
52 Week Low 4.7501
Average Volume 721,859
200-Day Moving Average 9.53
50-Day Moving Average 7.03
20-Day Moving Average 5.82
10-Day Moving Average 5.35
Average True Range 0.51
ADX 31.79
+DI 10.45
-DI 22.03
Chandelier Exit (Long, 3 ATRs ) 5.26
Chandelier Exit (Short, 3 ATRs ) 6.29
Upper Bollinger Band 6.87
Lower Bollinger Band 4.76
Percent B (%b) 0.22
BandWidth 36.28
MACD Line -0.56
MACD Signal Line -0.57
MACD Histogram 0.007
Fundamentals Value
Market Cap 239.13 Million
Num Shares 45.8 Million
EPS -1.95
Price-to-Earnings (P/E) Ratio -2.68
Price-to-Sales 34.40
Price-to-Book 7.62
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.66
Resistance 3 (R3) 5.67 5.55 5.58
Resistance 2 (R2) 5.55 5.44 5.54 5.56
Resistance 1 (R1) 5.38 5.37 5.47 5.37 5.53
Pivot Point 5.26 5.26 5.30 5.25 5.26
Support 1 (S1) 5.09 5.15 5.18 5.08 4.91
Support 2 (S2) 4.97 5.08 4.96 4.88
Support 3 (S3) 4.80 4.97 4.86
Support 4 (S4) 4.79